← Back to Search

Monoclonal Antibodies

RPT193 for Severe Asthma

Phase 2
Recruiting
Research Sponsored by RAPT Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Physician diagnosis of asthma for ≥6 months
Pre-bronchodilator FEV1 of >40% and <80%
Timeline
Screening 3 days
Treatment Varies
Follow Up 3 days
Awards & highlights

Study Summary

This trial will test a potential asthma treatment in people with severe asthma who are already taking meds.

Who is the study for?
This trial is for adults with moderate to severe T2-high asthma who are not fully controlled by medium or high doses of inhaled corticosteroids and long-acting beta 2 agonists. Participants should meet other specific health criteria not listed here.Check my eligibility
What is being tested?
The study tests RPT193 against a placebo in a randomized, double-blind setup where neither the participants nor the researchers know who receives which treatment until after the results are collected.See study design
What are the potential side effects?
Potential side effects of RPT193 aren't specified here, but common asthma medication side effects include throat irritation, headache, rapid heartbeat, and tremors.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 days
Treatment ~ Varies
Follow Up ~3 days
This trial's timeline: 3 days for screening, Varies for treatment, and 3 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants with a Loss of Asthma Control event as defined by criteria listed
Secondary outcome measures
Frequency of treatment-emergent adverse events as assessed by CTCAE v5.0

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: RPT193 400 mgExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RPT193
2019
Completed Phase 1
~110

Find a Location

Who is running the clinical trial?

RAPT Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
758 Total Patients Enrolled
Laurence Cheng, MD, PhDStudy DirectorRAPT Therapeutics, Inc.
1 Previous Clinical Trials
103 Total Patients Enrolled

Media Library

RPT193 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05935332 — Phase 2
Asthma Research Study Groups: RPT193 400 mg, Placebo
Asthma Clinical Trial 2023: RPT193 Highlights & Side Effects. Trial Name: NCT05935332 — Phase 2
RPT193 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05935332 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals aged 65 and younger being considered for this clinical experiment?

"This trial is enrolling adults aged between 18 and 75."

Answered by AI

Does this research endeavor currently accept participants?

"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially posted on July 1st 2023 and updated lastly on July 4th 2023, is currently seeking out participants. Approximately 100 patients are required for the study from 4 different medical centres."

Answered by AI

In what number of sites is this clinical investigation being overseen?

"The Allianz Research Institute CO in Aurora, Clinical Research Trials of Florida in Tampa and OK Clinical Research LLC in Edmond are just a few of the 4 sites actively involved with this trial."

Answered by AI

How many individuals have signed up to partake in this investigation?

"RAPT Therapeutics, Inc. require 100 eligible participants to commence the trial from their two operational sites: Allianz Research Institute CO located in Aurora, Colorado and Clinical Research Trials of Florida situated in Tampa, Florida."

Answered by AI

Do I meet the necessary criteria to participate in this experiment?

"This trial is actively seeking patients with asthma who are aged between 18 and 75. An approximate total of 100 people will be accepted into the study."

Answered by AI

To what extent may taking RPT193 400 mg be hazardous to individuals?

"Despite lacking any evidence for efficacy, there is already some data that indicates RPT193 400 mg's safety - thus giving it a score of 2."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
2023. "Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05935332.
All > Pediatric Asthma > Asthma
~59 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top